Foghorn Therapeutics (FHTX) Change in Acquisitions & Divestments (2021 - 2026)

Foghorn Therapeutics' Change in Acquisitions & Divestments history runs 6 years deep, the most recent figure standing at $49.2 million for Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments fell 38.9% year-over-year to $49.2 million; the TTM figure through Mar 2026 stood at $212.0 million (down 16.72% YoY), while the FY2025 annual figure was $243.3 million, up 4.67% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $49.2 million, up from $47.2 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $80.6 million in Q1 2025, with the low at $19.0 million in Q2 2022.
• The 5-year median for Change in Acquisitions & Divestments is $53.1 million (2022), against an average of $53.6 million.
• The sharpest annual moves came in 2022 and 2023: Change in Acquisitions & Divestments tumbled 79.89% in 2022, then jumped 303.02% in 2023.
• Foghorn Therapeutics' Change in Acquisitions & Divestments stood at $38.1 million in 2022, then increased by 16.17% to $44.3 million in 2023, then soared by 41.02% to $62.4 million in 2024, then declined by 24.36% to $47.2 million in 2025, then climbed by 4.25% to $49.2 million in 2026.
• Business Quant data shows FHTX's Change in Acquisitions & Divestments at $49.2 million in Q1 2026, $47.2 million in Q4 2025, and $39.6 million in Q3 2025.